

Patent Application
Attorney's Docket No. 016800-438

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) VIA FACSIMILE
Olivier de LACHARRIERE et al) 703 308 7922
Application No.: 09/841,078) Group Art Unit: 1619
Filed: April 25, 2001) Examiner: Lauren Wells
For: COSMETIC, PHARMACEUTICAL OR)
DERMATOLOGICAL COMPOSITION)
COMPRISING A HISTAMINE)
ANTAGONIST, AN INTERLEUKIN-1)
ANTAGONIST AND/OR A)
TNF-ALPHA ANTAGONIST)

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☒ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$ _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$ _____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26,254

Date: August 20, 2001

Patent Application #4
Attorney's Docket No. 016800-438
MP
5/14/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **VIA FACSIMILE:**
)
Olivier DE LACHARRIERE et al) (703) 308 7922
)
Application No.: 09/841,078) Group Art Unit: 1619
)
Filed: April 25, 2001) Examiner: Lauren Wells
)
For: COSMETIC, PHARMACEUTICAL)
OR DERMATOLOGICAL)
COMPOSITION COMPRISING A)
HISTAMINE ANTAGONIST, AN)
INTERLEUKIN-1 ANTAGONIST)
AND/OR A TNF-ALPHA)
ANTAGONIST)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AND CERTIFICATION UNDER 37 C.F.R. §1.97(e)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, and in supplement to the Information Disclosure Statement filed April 25, 2001, applicants are filing herewith a Form PTO-1449, Sheets 1-2, listing documents for consideration by the Examiner, and one copy of each of the listed documents.

It is respectfully requested that the Examiner consider the documents cited by applicants and return an initialed copy of the enclosed Form PTO-1449 to the undersigned.

I hereby certify that each item of information contained in the accompanying Form PTO-1449 was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Mary Katherine Baumeister

Mary Katherine Baumeister
Registration No. 26,254

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620
Date: August 20, 2001